发明授权
US5858393A Transdermal formulation 失效
透皮制剂

Transdermal formulation
摘要:
The present invention provides a method for treating a condition associated with muscarinic receptor modulation using a 3-�4-(butylthio)-1,2,5-thiadiazol-3-yl!-1-azabicyclo-�2.2.2!octane transdermal formulation. The invention provides desired transdermal 3-�4-(butylthio)-1,2,5-thiadiazol-3-yl!-1-azabicyclo�2.2.2!octane patch formulations.
公开/授权文献
信息查询
0/0